Literature DB >> 24325202

Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base.

Angela B Smith1, Allison M Deal, Michael E Woods, Eric M Wallen, Raj S Pruthi, Ronald C Chen, Matthew I Milowsky, Matthew E Nielsen.   

Abstract

OBJECTIVE: To evaluate the association between patterns of care and patient survival for the treatment of muscle-invasive bladder cancer (MIBC) using a large, national database. PATIENTS AND METHODS: We identified a cohort of 36,469 patients with MIBC (stage II) from 1998 to 2010 from the National Cancer Data Base. Patients were stratified into four treatment groups: radical cystectomy, chemo-radiation, other therapy, or no treatment. Overall survival (OS) among the groups was evaluated using Kaplan-Meier analysis and the log rank test. A multivariable Cox proportional hazards model was fit to evaluate the association between treatment groups and OS.
RESULTS: In all, 27% of patients received radical cystectomy, 10% chemo-radiation, 61% other therapy and 2% no treatment. Unadjusted Kaplan-Meier analysis showed significant differences by treatment group, with cystectomy having the greatest median OS (48 months) followed by chemo-radiation (28 months), other therapy (20 months), and no treatment (5 months). When controlling for multiple covariates, the OS for cystectomy was similar to that for chemo-radiation (hazard ratio [HR] 1.05, 95% confidence interval [CI] 0.98, 1.12), but superior to other therapy (HR 1.42; 95% CI 1.35, 1.48), and no treatment (HR 2.40; 95% CI 2.12, 2.72). The OS time for chemo-radiation was superior to other therapy and no treatment.
CONCLUSIONS: Radical cystectomy and chemo-radiation are significantly underused despite a substantial survival benefit compared with other therapies or no treatment. Future studies are needed to optimise care delivery and improve outcomes for patients with MIBC.
© 2013 The Authors. BJU International © 2013 BJU International.

Entities:  

Keywords:  bladder cancer; bladder-sparing therapy; radical cystectomy; treatment outcome; urinary bladder neoplasms

Mesh:

Year:  2014        PMID: 24325202     DOI: 10.1111/bju.12601

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  41 in total

Review 1.  Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy.

Authors:  Adnan El-Achkar; Luis Souhami; Wassim Kassouf
Journal:  Curr Urol Rep       Date:  2018-11-03       Impact factor: 3.092

2.  The perils of using registry data to compare the survival and cost of radical cystectomy and trimodality therapy in bladder cancer.

Authors:  Abhishek A Solanki; Stanley L Liauw
Journal:  Transl Androl Urol       Date:  2019-12

3.  Comparison of the efficacy and feasibility of laser enucleation of bladder tumor versus transurethral resection of bladder tumor: a meta-analysis.

Authors:  Huan Yang; Ning Wang; Shanfu Han; Musa Male; Chenming Zhao; Daqiang Yao; Zhiqiang Chen
Journal:  Lasers Med Sci       Date:  2017-08-23       Impact factor: 3.161

4.  Neoadjuvant Chemotherapy in Elderly Patients With Bladder Cancer: Oncologic Outcomes From a Single Institution Experience.

Authors:  Andrew R Leone; Kamran Zargar-Shoshtari; Gregory J Diorio; Pranav Sharma; David Boulware; Scott M Gilbert; Julio M Powsang; Jingsong Zhang; Wade J Sexton; Philippe E Spiess; Michael A Poch
Journal:  Clin Genitourin Cancer       Date:  2017-02-01       Impact factor: 2.872

5.  Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.

Authors:  Sam S Chang; Bernard H Bochner; Roger Chou; Robert Dreicer; Ashish M Kamat; Seth P Lerner; Yair Lotan; Joshua J Meeks; Jeff M Michalski; Todd M Morgan; Diane Z Quale; Jonathan E Rosenberg; Anthony L Zietman; Jeffrey M Holzbeierlein
Journal:  J Urol       Date:  2017-04-26       Impact factor: 7.450

Review 6.  Optimizing Nutrition Prior to Radical Cystectomy.

Authors:  Anthony D Oberle; Jeremy M West; Conrad M Tobert; Gabriel L Conley; Kenneth G Nepple
Journal:  Curr Urol Rep       Date:  2018-10-18       Impact factor: 3.092

Review 7.  Treatment of muscle invasive bladder cancer in the elderly: navigating the trade-offs of risk and benefit.

Authors:  Noam A VanderWalde; Michelle T Chi; Arti Hurria; Matthew D Galsky; Matthew E Nielsen
Journal:  World J Urol       Date:  2015-10-23       Impact factor: 4.226

Review 8.  Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions.

Authors:  Di Maria Jiang; Peter Chung; Girish S Kulkarni; Srikala S Sridhar
Journal:  Curr Oncol Rep       Date:  2020-02-01       Impact factor: 5.075

9.  Survival and Characteristics of Bladder Cancer: Analysis of the Malaysian National Cancer Registry.

Authors:  Mohd Nasrullah Nik Ab Kadir; Suhaily Mohd Hairon; Najib Majdi Yaacob; Azizah Ab Manan; Nabihah Ali
Journal:  Int J Environ Res Public Health       Date:  2021-05-14       Impact factor: 3.390

10.  Copy Number Variations of CEP63, FOSL2 and PAQR6 Serve as Novel Signatures for the Prognosis of Bladder Cancer.

Authors:  Zhao Cai; Huang Chen; Jingqiao Bai; Yang Zheng; Jianhui Ma; Xiongwei Cai; Yu Liu; Kaitai Zhang; Jianzhong Shou; Yanning Gao
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.